Fresenius Medical Care AG (NYSE:FMS) Shares Bought by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 349.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,314 shares of the company’s stock after buying an additional 1,799 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Fresenius Medical Care were worth $48,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Advisor Partners II LLC lifted its stake in Fresenius Medical Care by 16.3% in the third quarter. Advisor Partners II LLC now owns 10,836 shares of the company’s stock valued at $233,000 after buying an additional 1,518 shares during the last quarter. Inspire Investing LLC bought a new stake in Fresenius Medical Care in the third quarter valued at $600,000. First Trust Direct Indexing L.P. lifted its stake in Fresenius Medical Care by 6.6% in the third quarter. First Trust Direct Indexing L.P. now owns 23,888 shares of the company’s stock valued at $515,000 after buying an additional 1,482 shares during the last quarter. Signaturefd LLC lifted its stake in Fresenius Medical Care by 7.3% in the third quarter. Signaturefd LLC now owns 8,601 shares of the company’s stock valued at $185,000 after buying an additional 584 shares during the last quarter. Finally, Syon Capital LLC bought a new stake in Fresenius Medical Care in the third quarter valued at $384,000. Institutional investors and hedge funds own 8.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on FMS shares. Morgan Stanley cut shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a research note on Monday, January 8th. StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Friday. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Price Performance

NYSE:FMS traded up $0.33 during mid-day trading on Tuesday, reaching $21.04. 293,756 shares of the stock were exchanged, compared to its average volume of 432,760. The business has a fifty day moving average price of $19.51 and a 200 day moving average price of $19.52. The firm has a market capitalization of $12.35 billion, a PE ratio of 22.87, a PEG ratio of 1.10 and a beta of 1.00. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $27.72. The company has a current ratio of 1.42, a quick ratio of 1.07 and a debt-to-equity ratio of 0.47.

Fresenius Medical Care (NYSE:FMS) last released its earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11. The firm had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.32 billion. Fresenius Medical Care had a return on equity of 4.99% and a net margin of 2.56%. Research analysts expect that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Monday, June 3rd. Investors of record on Monday, May 20th will be paid a $0.437 dividend. The ex-dividend date is Friday, May 17th. This represents a yield of 2.35%. Fresenius Medical Care’s dividend payout ratio is currently 45.65%.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.